New therapy against mire metastases under Austrian management successfully tested

Vienna – An international research team led by MedUni Vienna and the AKH Vienna has achieved a success in the fight against the leptomeningeal metastatic disease (LMD) – a serious complication in advanced solid tumors that occur particularly in the case of breast and lung cancer. As part of a clinical study, the active ingredient Patritumab Deruxtecan (Her3-DXD) was tested for 20 patients with LMD for the first time.